---
layout: post
title: New Drug Approvals 2012 - Pt. XXVIII - Teduglutide (Gattex®)
date: '2013-01-06T03:21:00.000Z'
author: Ramesh
tags:
- Peptide Drugs
- 2012 New Drugs
modified_time: '2013-01-07T10:20:23.953Z'
blogger_id: tag:blogger.com,1999:blog-2546008714740235720.post-3511174651683167615
blogger_orig_url: http://chembl.blogspot.com/2013/01/new-drug-approvals-2012-pt-xxviii.html
---

<div dir="ltr" style="text-align: left;" trbidi="on">
<div class="separator" style="clear: both; text-align: center;">
<a href="http://www.gattex.com/images/gattex-logo.png" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" height="142" src="http://www.gattex.com/images/gattex-logo.png" width="320" /></a></div>
<div class="separator" style="clear: both; text-align: center;">
<br /></div>
<div class="separator" style="clear: both; text-align: center;">
<a href="https://www.ebi.ac.uk/chembltools/autoiconlarge/5,0,0,0,1,0,0,0,0" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" height="46" src="https://www.ebi.ac.uk/chembltools/autoiconlarge/5,0,0,0,1,0,0,0,0" width="400" /></a></div>
<br />
<div style="text-align: center;">
<b>ATC code:</b>&nbsp;A16AX08</div>
<div style="text-align: center;">
<b>Wikipedia:</b> <a href="http://en.wikipedia.org/wiki/Teduglutide">Teduglutide</a></div>
<br />
<div style="text-align: justify;">
On December 27, FDA approved Teduglutide (Tradename: Gattex®, Tradename: Revestive, Research Code: ALX-600, CAS# 197922-42-2), an analog of Glucagon-like peptide 2 (<a href="http://en.wikipedia.org/wiki/Glucagon-like_peptide-2" target="_blank">GLP2</a>) expressed in&nbsp;<i>Escherichia coli</i> by recombinant DNA (<a href="http://en.wikipedia.org/wiki/Recombinant_technology" target="_blank">rDNA</a>) technology indicated for the treatment of adult patients with Short Bowel Syndrome (<a href="http://en.wikipedia.org/wiki/Short_bowel_syndrome" target="_blank">SBS</a>).</div>
<br />
<div style="text-align: justify;">
Short Bowel Syndrome&nbsp;(MeSH:&nbsp;<a href="http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&amp;term=D012778">D012778</a>)&nbsp;is a condition in which nutrients are not properly absorbed (<a href="http://en.wikipedia.org/wiki/Malabsorption" target="_blank">malabsorption</a> disorder) caused by surgical removal of small intestine, or rarely due to the complete dysfunction of large segment of bowel. More information about SBS can be found in <a href="http://emedicine.medscape.com/article/193391-overview" target="_blank">Medscape</a>.</div>
<br />
<div style="text-align: justify;">
Teduglutide&nbsp;is an analog of naturally occurring&nbsp;Glucagon-like peptide 2 (GLP2), which is 33 amino acid peptide created by specific post-translational proteolytic cleavage of <a href="http://en.wikipedia.org/wiki/Proglucagon" target="_blank">proglucagon</a> in&nbsp;endocrine L cells of the distal&nbsp;intestine. GLP2 is known to increase intestinal and portal blood flow, and inhibit gastric acid secretion.</div>
<br />
<div style="text-align: justify;">
Teduglutide&nbsp;binds to Glucagon-like peptide-2 receptors (GLP-2R) located in subpopulations of <a href="http://en.wikipedia.org/wiki/Enteroendocrine_cells" target="_blank">enteroendocrine cells </a>of intestine,&nbsp;sub-epithelial&nbsp;<a href="http://en.wikipedia.org/wiki/Myofibroblast" target="_blank">myofibroblasts</a> and <a href="http://en.wikipedia.org/wiki/Enteric_neuron" target="_blank">enteric neurons</a> of the submucosal and myenteric plexus. Activation of these receptors results in local release of multiple mediators including Insulin-like growth factor (<a href="http://en.wikipedia.org/wiki/Insulin-like_growth_factor_1" target="_blank">IGF-1</a>), nitric oxide (<a href="http://en.wikipedia.org/wiki/Nitric_oxide#Biological_functions" target="_blank">NO</a>) and Keratinocyte growth factor (<a href="http://en.wikipedia.org/wiki/Keratinocyte_growth_factor" target="_blank">KGF</a>).</div>
<br />
<div style="text-align: justify;">
Glucagon-like peptide-2 receptors (<a href="http://en.wikipedia.org/wiki/Glucagon-like_peptide_2_receptor" target="_blank">GLP-2R</a>, <a href="https://www.ebi.ac.uk/chembldb/target/inspect/CHEMBL5844" target="_blank">CHEMBL5844</a>, <a href="http://www.uniprot.org/uniprot/O95838">O95838</a>), 553 amino acid long, is a receptor for glucagon-like peptide-2. The activity of this receptor is mediated by G proteins which activate adenylyl cyclase. The amino acid sequence of GLP-2R (<i>human</i>) is :</div>
<br />
<span style="font-family: Courier New, Courier, monospace;">&gt;GLP2R</span><br />
<span style="font-family: Courier New, Courier, monospace;">MKLGSSRAGPGRGSAGLLPGVHELPMGIPAPWGTSPLSFHRKCSLWAPGRPFLTLVLLVS</span><br />
<span style="font-family: Courier New, Courier, monospace;">IKQVTGSLLEETTRKWAQYKQACLRDLLKEPSGIFCNGTFDQYVCWPHSSPGNVSVPCPS</span><br />
<span style="font-family: Courier New, Courier, monospace;">YLPWWSEESSGRAYRHCLAQGTWQTIENATDIWQDDSECSENHSFKQNVDRYALLSTLQL</span><br />
<span style="font-family: Courier New, Courier, monospace;">MYTVGYSFSLISLFLALTLLLFLRKLHCTRNYIHMNLFASFILRTLAVLVKDVVFYNSYS</span><br />
<span style="font-family: Courier New, Courier, monospace;">KRPDNENGWMSYLSEMSTSCRSVQVLLHYFVGANYLWLLVEGLYLHTLLEPTVLPERRLW</span><br />
<span style="font-family: Courier New, Courier, monospace;">PRYLLLGWAFPVLFVVPWGFARAHLENTGCWTTNGNKKIWWIIRGPMMLCVTVNFFIFLK</span><br />
<span style="font-family: Courier New, Courier, monospace;">ILKLLISKLKAHQMCFRDYKYRLAKSTLVLIPLLGVHEILFSFITDDQVEGFAKLIRLFI</span><br />
<span style="font-family: Courier New, Courier, monospace;">QLTLSSFHGFLVALQYGFANGEVKAELRKYWVRFLLARHSGCRACVLGKDFRFLGKCPKK</span><br />
<span style="font-family: Courier New, Courier, monospace;">LSEGDGAEKLRKLQPSLNSGRLLHLAMRGLGELGAQPQQDHARWPRGSSLSECSEGDVTM</span><br />
<span style="font-family: Courier New, Courier, monospace;">ANTMEEILEESEI</span><br />
<br />
<div style="text-align: justify;">
Teduglutide, just like GLP2 and is 33 amino acids long, with a molecular weight of 3752.13 daltons. The recommended daily dose is 0.05 mg/kg body weight administered by subcutaneous injection once daily. The chemical structure was obtained from&nbsp;<a href="http://www.chemblink.com/products/197922-42-2.htm" target="_blank">Chemblink</a>.<br />
<br />
Amino acid sequence of&nbsp;Teduglutide&nbsp;is :&nbsp;<span style="font-family: Courier New, Courier, monospace;">His-Gly-Asp-Gly-Ser-Phe-Ser-Asp-Glu-Met-Asn-Thr-Ile-Leu-Asp-Asn-Leu-Ala-Ala-Arg-Asp-Phe-Ile-Asn-Trp-Leu-Ile-Gln-Thr-Lys-Ile-Thr-Asp</span></div>
<br />
<div class="separator" style="clear: both; text-align: center;">
<img border="0" height="293" src="http://www.chemblink.com/structures/197922-42-2.gif" width="400" /></div>
<br />
<div style="text-align: justify;">
After subcutaneous administration of Teduglutide in healthy individuals, the absolute bioavailability was 88% and maximum plasma concentrations was achieved in 3 to 5 hours, volume of distribution was 103 mL/kg and plasma clearance was approximately 123 mL/hr/kg with mean terminal half_life of approximately 2 hrs. Metabolic pathway of Teduglutide was not investigated in humans, however it is expected to be degraded into small peptides and amino acids via catabolic pathways similar to endogenous GLP-2.</div>
<br />
The license holder is <a href="http://www.npsp.com/" target="_blank">NPS Pharmaceuticals</a>, and the product website is <a href="http://www.gattex.com/">www.gattex.com</a>.<br />
<br />
Full prescribing information can be found <a href="http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Label_ApprovalHistory#labelinfo" target="_blank">he<span id="goog_885596099"></span><span id="goog_885596100"></span>re</a>.<br />
<br />
Ramesh<br />
<br /></div>
